500 Boylston Street, Boston, MA 02116 617-419-4700
Return to Results
RATIONALE: Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill
them or deliver tumor-killing substances to them without harming normal cells. Drugs used in
chemotherapy use different ways to stop tumor cells from dividing so they stop growing or
die. Combining monoclonal antibody therapy with chemotherapy may kill more tumor cells.
PURPOSE: Phase II trial to compare the effectiveness of trastuzumab alone and in combination
with docetaxel in treating patients who have metastatic prostate cancer that is refractory
to hormone therapy.
Ages:18 and older
DISEASE CHARACTERISTICS: - Histologically confirmed stage IV prostate cancer (any T, any N, M1, any G; D3) - Clinical evidence of metastatic disease in bone or soft tissue - Her2/neu-positive (2+ and 3+) by immunochemistry or fluorescent in situ hybridization - Androgen-independent - Serum PSA at least 10 ng/mL that has risen on 3 successive evaluations after prior hormonal therapy - At least 1 month since prior antiandrogen therapy (e.g., flutamide, bicalutamide, or nilutamide) and rising PSA levels with 1 of the 2 rising PSA levels, measured at least 2 weeks apart, after antiandrogen withdrawal - Bone only disease and elevated PSA alone allowed - LHRH analog therapy must continue in patients who have not had prior orchiectomy and have castrate levels of testosterone PATIENT CHARACTERISTICS: Age: - 18 and over Performance status: - SWOG 0-2 Life expectancy: - At least 12 weeks Hematopoietic: - WBC at least 3,500/mm3 - Absolute granulocyte count at least 1,800/mm3 - Platelet count at least lower limit of normal (LLN) Hepatic: - Bilirubin no greater than 2 times upper limit of normal (ULN) - SGOT no greater than 2 times ULN Renal: - Creatinine no greater than 1.6 mg/dL - Creatinine clearance at least 50 mL/min Cardiovascular: - Ejection fraction more than 50% or more than LLN by MUGA scan or 2-D echocardiogram - No symptomatic coronary artery disease - No active ischemia on EKG Other: - Fertile patients must use effective contraception - No other prior malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer PRIOR CONCURRENT THERAPY: Biologic therapy: - No concurrent biologic therapy Chemotherapy: - No more than one prior nonanthracycline chemotherapy regimen (including suramin) Endocrine therapy: - See Disease Characteristics - No concurrent corticosteroids as antiemetic Radiotherapy: - At least 4 weeks since prior radiotherapy - At least 3 months since prior strontium chloride Sr 89 and recovered - No concurrent radiotherapy to measurable lesions Surgery: - See Disease Characteristics
Sponsor: City of Hope Medical Center
Phase: Phase 2
Trial ID: NCT00005857
Not Accepting Healthy Volunteers